Citations

Showing 10 of 108081 citations.

Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis
Jaruvongvanich, Veeravich , Ahuja, Wasin , Wijarnpreecha, Karn , Ungprasert, Patompong , Wijarnpreecha, Karn

Mayo Clinic

European Journal of Gastroenterology & Hepatology | March 2, 2017 | Volume: 29 | Issue: 6 | Pages: 694-697

10.1097/meg.0000000000000865 | PMID 28252464 Get It

Background Uric acid is a natural antioxidant. Previous studies have suggested a protective role of hyperuricemia against liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD). However, the results were conflicting. Methods MEDLINE and EMBASE databases were searched through August 2016 for studies that investigated the association between hyperuricemia and fibrosis stage among patients with biopsy-proven NAFLD. Pooled odds ratio and 95% confidence interval were calculated using a random-effects model, generic inverse variance method of DerSimonian and Laird. The between-study heterogeneity of effect size was quantified using the Q statistic and I 2. Results A total of five observational studies with 749 NAFLD patients were identified. Patients with NAFLD who had hyperuricemia were not significantly more likely or less likely to have advanced liver fibrosis (defined as fibrosis stage of ≥3) compared with patients with NAFLD who had normal serum uric with the pooled odds ratio of 0.72 (95% confidence interval: 0.34–1.53). The statistical heterogeneity was low with an I 2 of 22% (P heterogeneity=0.27). Conclusion Significant protective role of hyperuricemia against the development of advanced liver fibrosis in patients with NAFLD was not observed in this meta-analysis.
Health‐relevant personality is associated with sensitivity to sound (hyperacusis)
Villaume, Karin , Hasson, Dan , Hasson, Dan , Hasson, Dan

Mayo Clinic

Scandinavian Journal of Psychology | March 2, 2017 | Volume: 58 | Issue: 2 | Pages: 158-169

10.1111/sjop.12350 | PMID 28252196 Get It

Hyperacusis, over‐sensitivity to sounds, causes distress and disability and the etiology is not fully understood. The study aims to explore possible associations between health‐relevant personality traits and hyperacusis. Hyperacusis was assessed using the Hyperacusis Questionnaire (HQ), and clinical uncomfortable loudness levels (ULL). Personality was measured with the Health‐relevant Personality (HP5i) Inventory. The study sample was 348 (140 men and 208 women; age 23–71 years). Moderate correlations were found between the personality trait negative affectivity (NA; a facet of neuroticism) and dimensions of the HQ and weak correlations were found with the ULLs. Hedonic capacity (a facet of extraversion) was significantly correlated with the HQ but not with the ULLs. Impulsivity (a facet of conscientiousness) was correlated with the HQ and the ULLs. A significant difference in mean values was found in all hyperacusis measures and different levels of NA – those with higher levels displayed more severe signs of hyperacusis. A multiple logistic regression analysis showed that higher levels of NA increases the odds of having hyperacusis on average 4.6 times for men and 2.4 times for women. These findings imply that health‐relevant personality traits should be considered in the diagnosis and treatment of hyperacusis.
Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations
Naidu, Sailendra , Şahin, Burcu , Mathur, Amit K. , Öklü, Rahmi , Deipolyi, Amy R. , Zhang, Yu , Khademhosseini, Ali , Borad, Mitesh J. , Oklu, Rahmi

Mayo Clinic

Journal of Clinical Medicine | March 2, 2017 | Volume: 6 | Issue: 3 | Pages: 26

10.3390/jcm6030026 | PMID 28257031 Get It

We characterized the effect of systemic therapy given after portal vein embolization (PVE) and before hepatectomy on hepatic tumor and functional liver remnant (FLR) volumes. All 76 patients who underwent right PVE from 2002–2016 were retrospectively studied. Etiologies included colorectal cancer (n = 44), hepatocellular carcinoma (n = 17), cholangiocarcinoma (n = 10), and other metastases (n = 5). Imaging before and after PVE was assessed. Chart review revealed systemic therapy administration, SNaPshot genetic profiling, and comorbidities. Nine patients received systemic therapy; 67 did not. Tumor volume increased 28% in patients who did not receive and decreased −24% in patients who did receive systemic therapy (p = 0.026), with no difference in FLR growth (28% vs. 34%; p = 0.645). Among 30 patients with genetic profiling, 15 were wild type and 15 had mutations. Mutations were an independent predictor of tumor growth (p = 0.049), but did not impact FLR growth (32% vs. 28%; p = 0.93). Neither cirrhosis, hepatic steatosis, nor diabetes impacted changes in tumor or FLR volume (p > 0.20). Systemic therapy administered after PVE before hepatic lobectomy had no effect on FLR growth; however, it was associated with decreasing tumor volumes. Continuing systemic therapy until hepatectomy may be warranted, particularly in patients with genetic mutations.
Sex Differences in Bicuspid Aortic Valve Adults
Mankad, Sunil , Mankad, Sunil V., Michelena, Héctor I.

Mayo Clinic

Circulation: Cardiovascular Imaging | March 2, 2017 | Volume: 10 | Issue: 3 | Pages: No page available

10.1161/circimaging.117.006123 | PMID 28251912 Get It

Consensus classification of posterior cortical atrophy
Crutch, Sebastian J. , Schott, Jonathan M. , Rabinovici, Gil D. , Murray, Melissa E. , Flier, Wiesje M. van der , Vandenberghe, Rik , Ahmed, Samrah , Bak, Thomas H. , Boeve, Bradley F., Butler, Christopher , Cappa, Stefano F. , Ceccaldi, Mathieu, Souza, Leonardo Cruz de , Dubois, Bruno, Félician, Olivier , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Hof, Patrick R., Krolak‐Salmon, Pierre , Lehmann, Manja , Magnin, Éloi , Mendez, Mario F. , Nestor, Peter J. , Onyike, Chiadi U. , Pelak, Victoria S. , Pijnenburg, Yolande A.L. , Primativo, Silvia , Rossor, Martin N. , Ryan, Natalie S. , Scheltens, Philip , González, Aida Suárez, Tang‐Wai, David F. , Yong, Keir , Carrillo, María C. , Fox, Nick C. , Murray, Melissa, Snowden, Julie S. , Dickerson, Bradford Clark , Boeve, Bradley F. , Galasko, Douglas , Hof, Patrick R. , Shakespeare, Timothy J. , Gonzalez, Aida Suarez , Murray, Melissa E , van der Flier, Wiesje M , Scheltens, Philip , Fox, Nick C , Yong, Keir X X , Rabinovici, Gil D , Schott, Jonathan M , Pijnenburg, Yolande A L , Vandenberghe, Rik

Mayo Clinic

Alzheimer's & Dementia | March 2, 2017 | Volume: 13 | Issue: 8 | Pages: 870-884

10.1016/j.jalz.2017.01.014 | PMID 28259709 Get It

Abstract Introduction A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings. Methods Consensus statements about PCA were developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web‐based quantitative survey regarding symptom frequency and the conceptualization of PCA. Results A three‐level classification framework for PCA is described comprising both syndrome‐ and disease‐level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico‐radiological syndrome. Classification level 2 (PCA‐pure, PCA‐plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA‐AD], Lewy body disease [PCA‐LBD], corticobasal degeneration [PCA‐CBD], prion disease [PCA‐prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome‐level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum. Discussion There was strong agreement regarding the definition of the core clinico‐radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single‐center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.
Preventing cardiovascular disease: Participant perspectives of the FAITH! Program
Dean, Patrick J., Lackore, Kandace A. , Jenkins, Sarah M. , Cohen, Consuelo, Johnson, Jacqueline , Ellis, Frances, Mangum, DC, Brewer, LaPrincess C. , Morrison, Eleshia J, Balls-Berry, Joyce E, Lackore, Kandace, Morrison, Eleshia J. P. , Balls‐Berry, Joyce E. , Hayes, Sharonne N. , Patten, Christi A.

Mayo Clinic

Journal of Health Psychology | March 2, 2017 | Volume: 24 | Issue: 12 | Pages: 1710-1723

10.1177/1359105317695878 | PMID 28810418 Get It

Striking cardiovascular health disparities exist among African-Americans in Minnesota compared to Whites; however, community-based interventions to address cardiovascular disease risk are lacking. This study explored participant perceptions of a culturally tailored, cardiovascular disease prevention program developed using a community-based participatory research process. Research participation perceptions, program benefits, and program satisfaction/acceptability were analyzed using a mixed-methods approach. Overall, acceptability was high. Findings highlight the favorable inclusion of African-Americans (research perception), knowledge gained about healthy lifestyle practices (benefits), and quality of the curriculum/speakers (satisfaction). Community-based participatory research may be useful in fostering the acceptability of behavior change interventions among marginalized African-American communities.
Abstract A71: Tumor HLA Class I expression influences immune cells infiltration in metastatic melanoma tumor microenvironment
Yan, Yiyi, Leontovich, Alexey A. , Flotte, Thomas J. , Gerdes, Michael, Santamaría-Pang, Alberto , Sood, Anup , Desai, Keyur , Zhang, Rong , Ginty, Fiona , Chadwick, Chrystal M. , Markovic, Svetomir N.

Mayo Clinic

Cancer Immunology Research | March 1, 2017 | Volume: 5 | Issue: 3_Supplement | Pages: A71-A71

10.1158/2326-6074.tumimm16-a71 Get It

Abstract The variable clinical success with immune checkpoint inhibitors in the treatment of solid tumors challenges us to further understand the regulatory mechanisms of immune cells infiltration – a critical step of tumor elimination – in a highly heterogenous tumor microenvironment (TME). Systemic analyses of the tumor-immune cell interface and interactions are of particular significance with direct clinical impact. We employed a multiplexed immunofluorescence (MxIF) method, a novel technology that allows in situ quantitative single cell characterization with high order protein multiplexing on whole tumor sections, to elucidate the key components in TME governing the immune cells' composition and function in metastatic melanoma lymph node metastases. Here, we show that the expression of tumor cell Human Leukocyte Antigen 1 (HLA-1) is highly heterogeneous both within the TME and between patients. The level of tumor HLA-1 expression directly correlates with the magnitude of cytotoxic T lymphocytes (CTLs) infiltration in the TME. In addition, decreased tumor HLA-1 expression is associated with accumulation of CD20+ cells at the edge of the tumor as well as an increased population of CD4+FOXP3+ cells. The association between tumor HLA-1 expression and immune cell distribution is highly consistent yet heterogenous across the entire tumor mass. Moreover, using quantitative single cell data, we developed algorithms for computational and spatial modeling of tumor-immune cell interfaces, allowing statistical comparison of cellular interactions in the context of tumor heterogeneity. Spatial analysis demonstrates that tumor HLA-1 expression favors CTL invasion, while lack of tumor HLA-1 expression results in CTL evasion. Furthermore, in a cohort of 166 Stage III melanoma patients, we confirm that CTLs infiltration is only present in regions with high tumor HLA-1 expressions, and that patients with tumors high in both tumor HLA-1 and CTLs have significantly improved progression free survival (PFS) compared with those with tumors low in HLA-1 and/or CTLs. Our study demonstrates that the heterogeneous tumor HLA-1 expression results in various immune cell distribution patterns in the TME, directly contributing to the varied antitumor immunities and ultimately influencing tumor outcomes. As part of the antigen presentation machinery, HLA-1 expression on tumors is necessary for CTLs infiltration and is indispensable for T cell mediated tumor elimination with direct clinical benefits. We also establish a novel platform for visualization and spatial representation of the cellular heterogeneity within the TME, providing data processing and modeling algorithms necessary for understanding the cellular interplay mediating tumor surveillance, which will ultimately improve therapeutic efficacy and clinical outcomes. Citation Format: Yiyi Yan, Alexey Leontovich, Thomas Flotte, Michael Gerdes, Fiona Ginty, Alberto Santamaria-Pang, Anup Sood, Keyur Desai, Chrystal Chadwick, Rong Zhang, Svetomir N. Markovic. Tumor HLA Class I expression influences immune cells infiltration in metastatic melanoma tumor microenvironment. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2016 Oct 20-23; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2017;5(3 Suppl):Abstract nr A71.
Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism
Mishra, Vivek Kumar , Subramaniam, Malayannan , Kari, Vijayalakshmi, Pitel, Kevin S., Baumgart, Simon J., Naylor, Ryan M. , Nagarajan, Sankari , Ellenrieder, Volker , Hawse, John R. , Johnsen, Steven A. , Wegwitz, Florian , Johnsen, Steven A

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 9 | Pages: 2387-2400

10.1158/0008-5472.can-16-2589 | PMID 28249899 Get It

Abstract TGFβ–SMAD signaling exerts a contextual effect that suppresses malignant growth early in epithelial tumorigenesis but promotes metastasis at later stages. Longstanding challenges in resolving this functional dichotomy may uncover new strategies to treat advanced carcinomas. The Krüppel-like transcription factor, KLF10, is a pivotal effector of TGFβ/SMAD signaling that mediates antiproliferative effects of TGFβ. In this study, we show how KLF10 opposes the prometastatic effects of TGFβ by limiting its ability to induce epithelial-to-mesenchymal transition (EMT). KLF10 depletion accentuated induction of EMT as assessed by multiple metrics. KLF10 occupied GC-rich sequences in the promoter region of the EMT-promoting transcription factor SLUG/SNAI2, repressing its transcription by recruiting HDAC1 and licensing the removal of activating histone acetylation marks. In clinical specimens of lung adenocarcinoma, low KLF10 expression associated with decreased patient survival, consistent with a pivotal role for KLF10 in distinguishing the antiproliferative versus prometastatic functions of TGFβ. Our results establish that KLF10 functions to suppress TGFβ-induced EMT, establishing a molecular basis for the dichotomy of TGFβ function during tumor progression. Cancer Res; 77(9); 2387–400. ©2017 AACR.
Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment
Gomez-Chou, Sobeyda B., Świdnicka‐Siergiejko, Agnieszka , Badi, Niharika , Chavez-Tomar, Myrriah , Bekaii‐Saab, Tanios , Mace, Thomas A. , Schmidt, Carl , Liu, Yan , Deng, Defeng , Hwang, Rosa F. , Zhou, Liran , Moore, Todd T., Leng, Xiaohong , Arlinghaus, Ralph B., Logsdon, Craig D. , Cruz‐Monserrate, Zobeida , Lesinski, Gregory B , Farren, Matthew R. , Chatterjee, Deyali , Wang, Huamin , Bekaii-Saab, Tanios S

Mayo Clinic

Cancer Research | March 1, 2017 | Volume: 77 | Issue: 10 | Pages: 2647-2660

10.1158/0008-5472.can-16-1986 | PMID 28249896 Get It

Abstract Lipocalin-2 (LCN2) promotes malignant development in many cancer types. LCN2 is upregulated in patients with pancreatic ductal adenocarcinoma (PDAC) and in obese individuals, but whether it contributes to PDAC development is unclear. In this study, we investigated the effects of Lcn2 depletion on diet-induced obesity, inflammation, and PDAC development. Mice with acinar cell–specific expression of KrasG12D were crossed with Lcn2-depleted animals and fed isocaloric diets with varying amounts of fat content. Pancreas were collected and analyzed for inflammation, pancreatic intraepithelial neoplasia (PanIN), and PDAC. We also used a syngeneic orthotopic PDAC mouse model to study tumor growth in the presence or absence of Lcn2 expression. In addition, to understand the mechanistic role of how LCN2 could be mediating PDAC, we studied LCN2 and its specific receptor solute carrier family 22 member 17 (SLC22A17) in human pancreatic cancer stellate cells (PSC), key mediators of the PDAC stroma. Depletion of Lcn2 diminished extracellular matrix deposition, immune cell infiltration, PanIN formation, and tumor growth. Notably, it also increased survival in both obesity-driven and syngeneic orthotopic PDAC mouse models. LCN2 modulated the secretion of proinflammatory cytokines in PSC of the PDAC tumor microenvironment, whereas downregulation of LCN2-specific receptor SLC22A17 blocked these effects. Our results reveal how LCN2 acts in the tumor microenvironment links obesity, inflammation, and PDAC development. Cancer Res; 77(10); 2647–60. ©2017 AACR
Pulmonologists’ and Primary Care Physicians’ Responses to an Adult Patient with Asthma Who Inquires about Using Electronic Cigarettes as a Smoking Cessation Tool
Nickels, Andrew S., Jenkins, Sarah M. , Tilburt, Jon C. , Hays, J. Taylor , Warner, David O.

Mayo Clinic

Annals of the American Thoracic Society | March 1, 2017 | Volume: 14 | Issue: 3 | Pages: 466-468

10.1513/annalsats.201610-828le | PMID 28248581 Get It